# Qiming Venture Partners

> Qiming Venture Partners is a VC fund backing Health Care and Biotechnology. See 905 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 905
- Last investment: Jul 2026
- Lead investor: 45%
- Fund size: $887M
- Last fund: May 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/10364438
- X (Twitter): http://twitter.com/QimingVC
- Website: http://www.qimingvc.com

Qiming Venture Partners is a VC fund in Shanghai focused on Health Care and Biotechnology. Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

## Contacts

5 contacts available for Qiming Venture Partners. Shizune tracks 17 team members at Qiming Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/qiming-venture-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5M–$67M |
| Series B | $9.4M–$100M |
| Series C | $15M–$134M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 109 | 12% |
| Biotechnology | 94 | 10% |
| Medical | 90 | 10% |
| Pharmaceutical | 46 | 5% |
| Artificial Intelligence | 45 | 5% |

236 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 175 | 19% |
| Series A | 162 | 18% |
| Series C | 94 | 10% |
| Seed | 52 | 6% |
| Series D | 42 | 5% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 333 | 37% |
| United States | 48 | 5% |
| Hong Kong | 11 | 1% |
| Singapore | 6 | 1% |
| Indonesia | 3 | 0% |

14 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Grace Lee | Partner & CFO | 0 | https://shizune.co/investors/profile/grace-lee-4 |
| Jinda Gao | Principal | 11 | https://shizune.co/investors/profile/jinda-gao |
| Oscar Zhang | Principal | 27 | https://shizune.co/investors/profile/oscar-zhang-2 |
| Shiyu Wang | Partner | 13 | https://shizune.co/investors/profile/shiyu-wang |
| Alexander Sinclair-Wilson | Principal | 4 | https://shizune.co/investors/profile/alexander-sinclair-wilson-99ee |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Blue Emergence | Blue Emergence is a marine technology consumer products company, |  | Angel | Jul 24, 2026 |  |
| Fibrox | Fibrox develops innovative cell therapies based on fibroblasts and clinical requirements for patients. | $3.7M | Series A | Jul 21, 2026 |  |
| Mufan Power | Mufan Power is a new energy high-tech enterprise in the field of turbomachinery. It is committed to the development of a new generation of zero-carbon hydrogen power generation technologies and products. Its main products are hydrogen gas turbines, which can be used in distributed energy and data centers. , rail transit, ship power, vehicle power,energy storage peak shaving and other carbon neutral scenarios. |  | Series C | Jul 13, 2026 |  |
| Tianhu Technology | Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. |  | Series A | Jul 13, 2026 |  |
| Kling AI | Kling AI is an AI-powered creative studio for creating imaginative images and videos, based on state-of-the-art generative AI methods. | $2.8B | Venture - Series Unknown | Jul 01, 2026 |  |
| Dongsheng Fusion | Dongsheng Fusion is a magnetic confinement fusion technology company that develops miniaturized fusion power plant technology. | $100M | Seed | Jun 08, 2026 |  |
| Dongsheng Fusion | Dongsheng Fusion is a magnetic confinement fusion technology company that develops miniaturized fusion power plant technology. |  | Seed | May 27, 2026 |  |
| Makera | Makera is essentially creating a maker's dream CNC machine; we use it every day for various projects and enjoy the experience, and we hope you will too. | $14.7M | Series A | May 06, 2026 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| Microtide Biotechnology | Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M | Series A | Apr 29, 2026 |  |

10 of 905 investments shown.

## Co-investors
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 41 deals together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 40 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 36 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 30 deals together
- [TF Capital](https://shizune.co/investors/profile/tf-capital) — VC Fund, 25 deals together
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 24 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund

## Featured in investor lists
- [All Investors](https://shizune.co/investors/investors)
- [All Investors in Asia](https://shizune.co/investors/investors-asia)
- [All VC Funds in Asia](https://shizune.co/investors/vc-funds-asia)
- [All Investors in China](https://shizune.co/investors/investors-china)
- [All VC Funds in China](https://shizune.co/investors/vc-funds-china)
- [Health Care Investors](https://shizune.co/investors/health-care-investors)

## FAQ

### What does Qiming Venture Partners invest in?

Qiming Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 905 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Qiming Venture Partners's check size?

Qiming Venture Partners typically joins rounds of $5M–$67M at Series A, $9.4M–$100M at Series B and $15M–$134M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Qiming Venture Partners participates in.

### How do I contact Qiming Venture Partners?

Public channels for Qiming Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Qiming Venture Partners?

The team at Qiming Venture Partners includes Grace Lee (Partner & CFO), Jinda Gao (Principal) and Oscar Zhang (Principal), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co